Company Interview / Adherium’s big breath of success

Key points:

Adherium (ASX:ADR) reports 235% increase in medication adherence from ‘icare’ study Hayley platform provides remote monitoring and AI-driven patient prompts Study data suggests reduction in hospitalisations and healthcare costs Ongoing enrolment and international expansion indicated by Bitz

Adherium (ASX:ADR) has reported promising preliminary results from its recent ‘icare’ study, revealing the impact of its Hayley platform and smart inhaler sensors in transforming respiratory health management. Dawn Bitz states that the study, conducted with Intermountain Health and Care Center in the United States, covers almost a thousand patients with COPD and asthma, historically a challenging group for adherence to medication. Bitz points out that Hayley’s connected device sits atop standard inhalers, tracking use and effectiveness, and enabling remote monitoring by clinicians.

Bitz highlights a significant 235% increase in patient adherence to inhaler use compared to typical historical rates. This improvement, according to Bitz, could lead to fewer hospitalisations, emergency department visits and a reduction in overall healthcare costs. The platform leverages AI-driven monitoring, offering patients real-time prompts and enabling healthcare providers to intervene early, addressing health issues before they escalate in the period between clinic visits.

Despite recent share price challenges for Adherium, Bitz mentions growing interest from both investors and health systems internationally. Ongoing trials and international activity aim to further validate the role of Adherium’s Hayley solutions in improving outcomes and lowering costs for chronic respiratory conditions.